A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis

Michael J. Borucki, John Spritzler, David Asmuth, John Gnann, Martin S. Hirsch, Mostafa Nokta, Francesca Aweeka, Paul I. Nadler, Fred Sattler, Beverly Alston, Thomas T. Nevin, Susan Owens, Karen Waterman, Larry Hubbard, Angela Caliendo, Richard B Pollard

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Fingerprint Dive into the research topics of 'A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis'. Together they form a unique fingerprint.

Medicine & Life Sciences